Connect with us

Business

The Israeli Ministry of Health and Helsinki Approves a Phase IIa Clinical Trial of SCI-110, a Treatment for Alzheimer’s disease and Agitation, SciSparc Ltd (OTCMKTS: SPRCY) says

Published

on

Alzheimer’s disease (AD) may not be as common as many other neurodegenerative diseases. However, it can be very traumatizing once it occurs. The irreversible condition causes progressive and disabling impairment of cognitive functions, including reasoning and judgment, memory, and attention. The sad news is that the current day treatment for AD is somewhat satisfactory. But on the other hand, SciSparc Ltd (OTCMKTS: SPRCY) says they have received approval to commence a Phase IIa Clinical Trial of a potential treatment, SCI-110. Thanks to the Israeli Ministry of Health and Helsinki Committee. 

SCI-110, formerly THX-110, is a combination of many elements. Dronabinol, an FDA-Approved, CannAmide and synthetic version of delta-9-tetrahydrocannabinol (Δ⁹-THC). According to the company, the combinations boost the integral properties of different cannabinoids, which is Dronabinol. And while there have been positive results in the pre-clinical studies, the approved would likely replicate the same. 

The Primary Goal of Creating and Enhancing a Portfolio of Cannabinoid-Based Treatments

The demand for quality cannabinoid-based treatments is on the rise. Hence, the approval of the clinical trial is timely. Principal Investigator and board-certified geriatrician, Dr. Alona Raveh, will head the study scheduled at The Israeli Medical Center for Alzheimer’s. The primary objective is to demonstrate the safety of SCI-110, tolerability, and ability to alleviate agitation in patients with AD. 

“We are very excited to begin our trial… we believe that this trial will corroborate our belief that SCI-110 may constitute a safe and effective treatment for agitation in Alzheimer’s disease.” Chief Technologies Officer of SciSparc Dr. Adi Zuloff-Shani announced

Meanwhile, the company focuses on developing several drugs such as SCI-160 (formerly THX-160), a pain treatment, and SCI-210 (formerly THX-210) for autism spectrum disorder and epilepsy. It is worth mentioning SciSparc Ltd engages an experienced team of senior executives and scientists, people who are well versed with the pharmaceutical industry and primarily in the use of CBD products. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES

Business4 hours ago

SōRSE Technology Corp Gives Vext Science Inc. (OTCMKTS: VEXTF) Exclusive Rights to Sell its MAJOR Cannabis-Infused Beverages in Arizona

Post Views: 2 Just like many other institutions across the globe, the pandemics and public health emergencies, including those related...

Business4 hours ago

CONSERVATIVE BROADCAST MEDIA JOURNALISM Ord Shs (OTCMKTS: CBMJ) Records $1.827M in Revenue for the First Six Months of 2021 Achieving Its First-Ever Quarterly Sales Exceeding $1.0M

Post Views: 25 The most valuable asset an industry could offer is information and knowledge. CONSERVATIVE BROADCAST MEDIA JOURNALISM Ord...

Business4 hours ago

Livewire Ergogenics Inc. (OTCMKTS: LVVV) Receives Authorization to Operate Commercial Cannabis Business from the County of San Luis Obispo, California

Post Views: 38 Cannabinoid products are ubiquitous today in the health and wellness industry. Many companies are consistently pushing in...

Business5 hours ago

The Israeli Ministry of Health and Helsinki Approves a Phase IIa Clinical Trial of SCI-110, a Treatment for Alzheimer’s disease and Agitation, SciSparc Ltd (OTCMKTS: SPRCY) says

Post Views: 34 Alzheimer’s disease (AD) may not be as common as many other neurodegenerative diseases. However, it can be...

Business1 day ago

Canada House Wellness Group Inc.’s (OTCMKTS: SARSF) Subsidiary Abba Medix Corp Hits 1000 Enrolments

Post Views: 16 Canada House Wellness Group Inc. (OTCMKTS: SARSF) has announced that its subsidiary Abba Medix Corp has hit...

Business1 day ago

Tilray Inc.’s (NASDAQ: TLRY) Completes First Cannabis Harvest From Its Germany Facility

Post Views: 20 Tilray Inc.’s (NASDAQ: TLRY) Germany subsidiary, Aphria RX GmbH, has concluded the first medical cannabis harvest grown...